SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 28, 2004
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission file Number) | (IRS Employer ID Number) |
| 8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615 | ||
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code (919) 862-1000
| Item 5. | Other Events and Regulation FD Disclosure |
On January 28, 2004, Salix Pharmaceuticals, Ltd. (the “Registrant”) issued a press release announcing that the Registrant will report fourth quarter and year ended December 31, 2003 financial results before the market opens on Tuesday, February 3, 2004.
| Item 7. | Financial Statements and Exhibits. |
| (c) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press release dated January 28, 2004, announcing that the Registrant will report fourth quarter and year ended December 31, 2003 financial results before the market opens on Tuesday, February 3, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 28, 2004 | SALIX PHARMACEUTICALS, LTD.
By: /s/ Adam C. Derbyshire Adam C. Derbyshire Senior Vice President and Chief Financial Officer |
